Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899078 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02899078 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 31 participants.
The verdict
NCT02899078, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.
Interventions
- DRUG Nivolumab
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899078
The ClinicalTrials.gov registry entry for NCT02899078 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02899078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02899078 about?
NCT02899078 is a clinical study titled "Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer". This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such...
What is the current status of trial NCT02899078?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2016-11-15. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT02899078?
The interventions under investigation include: Nivolumab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02899078?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.